SYNGENE INTERNATIONAL LTD Valuation
SYNGENE · Healthcare · Current price ₹402.1
Is SYNGENE INTERNATIONAL LTD undervalued?
DocStoX estimates the fair value of SYNGENE INTERNATIONAL LTD at ₹264 per share, versus the current market price of ₹402. That puts the stock about -34.4% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 4 independent methods: Residual income (₹92), Relative P/E (₹490), Graham floor (₹140), Analyst target (₹502). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹92 (bear) to ₹264 (base) to ₹502 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
Valuation multiples
SYNGENE INTERNATIONAL LTD trades at a P/E of 32.6x and a P/B of 3.5x, with a dividend yield of 0.3%. Multiples are most useful compared against the company's own history and its sector peers — see the peer comparison for context.
Understand the ratios
More on SYNGENE INTERNATIONAL LTD
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.